CTRI/2016/12/007593Other3 期
An open label, single-arm, multicentre study to evaluate safety and efficacy of Nutricharge Energy Drink in healthy human volunteers in India - Nutricharg Energy Drink
Trophic Wellness Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a) Age group: 18 years - 40 years
- •b) Subjects in good physical condition and sound mental status.
- •c) In the judgment of the Principal Investigator, able to comply with protocol requirements.
- •d) Subjects passing all the screening tests
- •e) Subjects willing to sign written informed consent
排除标准
- •a) Pre Diabetic & Diabetic Subjects
- •b) Pre-hypertensive & Hypertensive subjects
- •c) Subjects addicted to alcohol, Drugs of Abuse or tobacco
- •d) Hypersensitivity to study product or any contents of the energy drink
- •e) Presence of any major illness such as cancer, heart disease, COPD, Asthma etc.
- •f) Subjects with current medical history of any major illness such as cancer, heart disease, COPD , Asthma etc. in the past
- •g) Subjects with history of any acute or chronic illness that may affect the patientâ??s participation in the study
- •h) Current use of vitamin or mineral supplements, nutritional supplements and or medical foods within 30 days prior to the beginning of the study and for the duration of the study.
- •i) Use of prescription medications and/or nonprescription medications for acute medical conditions, semi-acute medical conditions, and weight loss.
- •j) Subjects with acute illness or history of major or minor surgery in the past one year.
- •k) Female subjects who are currently pregnant and/or breast feeding
- •l) Subjects receiving any medical therapy for any illness.
研究者
相似试验
招募中
2 期
Study to evaluate the safety and efficacy of sacubitril valsartan under hemodialysisChronic heart failureJPRN-jRCT1031230599Asanuma Katsuhiko32
招募中
1 期
Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraThrombotic Thrombocytopenic PurpuraMedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2022-001177-31-ATSanofi-Aventis Recherche & Développement64
招募中
1 期
Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraMedDRA version: 20.0Level: PTClassification code: 10043648Term: Thrombotic thrombocytopenic purpura Class: 100000004851Thrombotic Thrombocytopenic PurpuraCTIS2024-513262-19-00Sanofi-Aventis Recherche & Developpement71
进行中(未招募)
1 期
Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraMedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersThrombotic Thrombocytopenic PurpuraEUCTR2022-001177-31-DESanofi-Aventis Recherche & Développement64
尚未招募
3 期
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpuraNL-OMON53928Sanofi BV2
